• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cilazapril prevents hypertension in spontaneously hypertensive rats.

作者信息

Hefti F, Fischli W, Gerold M

出版信息

J Cardiovasc Pharmacol. 1986 May-Jun;8(3):641-8. doi: 10.1097/00005344-198605000-00030.

DOI:10.1097/00005344-198605000-00030
PMID:2425185
Abstract

Chronic daily administration of cilazapril (1 X 10 mg/kg/day p.o., from age 4 to 14 weeks) to young spontaneously hypertensive rats (SHR) prevented the development of hypertension. The antihypertensive effect of a single dose of cilazapril persisted greater than 24 h. Discontinuation of long-term treatment resulted in an increase of systolic arterial blood pressure (SAP) to control hypertensive levels within 4 days. Following 10 weeks of drug administration, comparative hemodynamic studies were carried out on age-matched (14 weeks) control SHR and cilazapril-treated SHR. Cilazapril-treated SHR had a significantly lower mean arterial blood pressure (MAP) and total peripheral vascular resistance than did control SHR. The antihypertensive effect of cilazapril was not associated with changes in heart rate (HR). The myocardial performance parameters, cardiac output, and stroke volume, were similar in treated and control SHR, suggesting that the antihypertensive effect of cilazapril following chronic administration to SHR is mainly due to a reduction in peripheral vascular resistance. Vasopressor responses to angiotensin I were significantly lower in cilazapril-treated SHR than in control SHR. By contrast, pressor responses to angiotensin II and a high dose of norepinephrine (1.0 microgram/kg i.v.) were significantly enhanced. Isoproterenol elicited a fall in blood pressure in both groups, the extent of which was dependent upon the magnitude of basal blood pressure levels. Chronic cilazapril treatment resulted in a reduction of heart weight, suggesting that the drug may prevent development of cardiac hypertrophy in SHR. Kidney and adrenal weights were unaffected by the chronic treatment. Specific renin activities (SRA) in tissues of SHR were increased by factors of 20 (plasma) or 2 (kidney and adrenal) following cilazapril administration.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Cilazapril prevents hypertension in spontaneously hypertensive rats.
J Cardiovasc Pharmacol. 1986 May-Jun;8(3):641-8. doi: 10.1097/00005344-198605000-00030.
2
Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.急性和慢性西拉普利治疗对自发性高血压大鼠的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):151S-158S. doi: 10.1111/j.1365-2125.1989.tb03476.x.
3
Effects of chronic therapy with cilazapril, a new angiotensin-converting enzyme inhibitor, on regional blood flows in conscious spontaneously hypertensive rats.
J Cardiovasc Pharmacol. 1987 Sep;10(3):350-5. doi: 10.1097/00005344-198709000-00015.
4
Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study.西拉普利对自发性高血压大鼠视网膜血管的影响:铸型腐蚀及扫描电子显微镜研究
Life Sci. 1999;64(3):PL27-39. doi: 10.1016/s0024-3205(98)00554-2.
5
Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.慢性ETA选择性内皮素受体拮抗剂对大鼠实验性高血压和遗传性高血压血压的影响。
Br J Pharmacol. 1997 Jul;121(5):935-40. doi: 10.1038/sj.bjp.0701224.
6
Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression.用Nω-硝基-L-精氨酸甲酯治疗的自发性高血压大鼠中内皮素拮抗作用与血管紧张素转换酶抑制作用对血压和血管结构的影响比较。与血管内皮素-1基因表达的拓扑学相关性。
Hypertension. 1996 Aug;28(2):188-95. doi: 10.1161/01.hyp.28.2.188.
7
Chronic administration of tiapamil prevents hemodynamic alterations accompanying development of high blood pressure in hypertensive rats.慢性给予替帕米能预防高血压大鼠高血压发展过程中伴随的血流动力学改变。
J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1192-200.
8
Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs.
J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):99-108. doi: 10.1097/00005344-198601000-00016.
9
Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats.
Hypertension. 1990 Nov;16(5):532-40. doi: 10.1161/01.hyp.16.5.532.
10
The angiotensin I-converting enzyme inhibitor, cilazapril inhibits the platelet-derived growth factor B chain expression in glomeruli of spontaneously hypertensive rats.血管紧张素I转换酶抑制剂西拉普利可抑制自发性高血压大鼠肾小球中血小板衍生生长因子B链的表达。
Ren Physiol Biochem. 1995 Sep-Oct;18(5):237-45. doi: 10.1159/000173921.

引用本文的文献

1
Preclinical studies on angiotensin converting enzyme inhibitors.血管紧张素转换酶抑制剂的临床前研究。
Cardiovasc Drugs Ther. 1987;1(1):15-27. doi: 10.1007/BF02125829.
2
The influence of food on the pharmacokinetics and ACE inhibition of cilazapril.食物对西拉普利药代动力学及血管紧张素转换酶抑制作用的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):205S-209S. doi: 10.1111/j.1365-2125.1989.tb03483.x.
3
The pharmacokinetics and dose proportionality of cilazapril.西拉普利的药代动力学及剂量比例关系。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):199S-204S. doi: 10.1111/j.1365-2125.1989.tb03482.x.
4
Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.慢性心力衰竭对大鼠血管紧张素I反应性及西拉普利抑制血管紧张素转换酶作用的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):167S-174S. doi: 10.1111/j.1365-2125.1989.tb03478.x.
5
Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.急性和慢性西拉普利治疗对自发性高血压大鼠的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):151S-158S. doi: 10.1111/j.1365-2125.1989.tb03476.x.
6
Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.
Drugs. 1991 May;41(5):799-820. doi: 10.2165/00003495-199141050-00008.
7
Vascular protection with cilazapril.
Drugs. 1991;41 Suppl 1:62-7. doi: 10.2165/00003495-199100411-00011.